Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

MNOV
Medicinova, Inc.
stock NASDAQ

At Close
Dec 8, 2025 3:59:59 PM EST
1.52USD-2.564%(-0.04)66,411
0.00Bid   0.00Ask   0.00Spread
Pre-market
Dec 8, 2025 9:15:30 AM EST
1.54USD-1.231%(-0.02)748
After-hours
Dec 8, 2025 4:12:30 PM EST
1.50USD-1.316%(-0.02)1,811
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
06:31AM EST  MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For Hepatic Ballooning In Canada   Benzinga
06:30AM EST  MediciNova Receives a Notice of Allowance for a New Patent   GlobeNewswire Inc
Jan 27, 2022
06:30AM EST  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from theEuropean Patent Officefor a pending patent applicationwhich covers MN-166 (ibudilast) for the treatment of alcohol use disorder.   GlobeNewswire Inc
Jan 26, 2022
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
06:34AM EST  MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe   Benzinga
06:30AM EST  MediciNova Receives a Notice of Intention to Grant for a New   GlobeNewswire Inc
Dec 13, 2021
06:34AM EST  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For The Treatment Of ALS   Benzinga
06:30AM EST  MediciNova Receives Notice of Allowance forNew Patent   GlobeNewswire Inc
Dec 10, 2021
06:33AM EST  MediciNova Reports MN-166 Poster Presentation For Int'l. Symposium On Amyotrophic Lateral Sclerosis/Motor Neurone Disease Dec. 7-10   Benzinga
06:30AM EST  MediciNova Announces MN-166 (ibudilast) Poster Presentation at the   GlobeNewswire Inc
Nov 23, 2021
09:43AM EST  Zacks Small-Cap Research Sets $27 Valuation On MediciNova   Benzinga
Nov 22, 2021
06:32AM EST  MediciNova Announces New Data Regarding MN-166 In Glioblastoma Presented At The 26th Annual Meeting Of The Society For Neuro-Oncology   Benzinga
06:30AM EST  MediciNova Announces New Data regarding MN-166 (ibudilast) in   GlobeNewswire Inc
Nov 11, 2021
06:01PM EST  MediciNova Announces MN-001 Data Regarding Lipid Metabolism In NASH/NAFLD To Be Presented At The Liver Meeting 2021   Benzinga
06:00PM EST  MediciNova Announces MN-001 (tipelukast) Data regarding Lipid   GlobeNewswire Inc
Nov 10, 2021
06:48PM EST  MediciNova Highlights New Data Related To MN-166 In Uveal Melanoma Presented At CURE Global Science Meeting   Benzinga
Oct 21, 2021
12:11PM EDT  MediciNova Announces Abstract Regarding The Mechanism By Which MN-001 Alters Triglyceride Metabolism Accepted For Presentation At The 19th International Symposium On Atherosclerosis   Benzinga
06:30AM EDT  MediciNova Announces Abstract regarding the Mechanism by which   GlobeNewswire Inc
Sep 2, 2021
11:00PM EDT  MediciNova to Participate in the Morgan Stanley 19th Annual Global   GlobeNewswire Inc
Sep 1, 2021
06:30AM EDT  MediciNova Announces MN-001 Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting 2021   Benzinga
06:30AM EDT  MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid   GlobeNewswire Inc
Aug 30, 2021
06:31AM EDT  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND   Benzinga
06:30AM EDT  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for   GlobeNewswire Inc
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
10:14AM EDT  MediciNova Granted U.S. Patent Titled 'Treatment of progressive neurodegenerative disease with ibudilast'   Benzinga
Aug 2, 2021
04:52PM EDT  MediciNova Announces Effective July 31, 2021, Edward Stepanow Resigned As Chief Financial Officer; Douglas Paulin To Serve CFO   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 6, 2021
06:33AM EDT  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For The Treatment Of Ophthalmic Disease   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from theU.S.Patent andTrademark Officefor a pending patent application which covers MN-166 (ibudilast) for the treatment of ophthalmic disease.   GlobeNewswire Inc
Jun 29, 2021
06:30AM EDT  MediciNova to Present at the Ladenburg Thalmann 2021 Virtual   GlobeNewswire Inc
Jun 28, 2021
08:37AM EDT  MediciNova To Test Ibudilast In BARDA's Validated Mouse Model Of Chlorine-Induced Pulmonary Injury   Benzinga
06:31AM EDT  MediciNova To Conduct Mouse Study Under Partnership With BARDA To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury   Benzinga
06:30AM EDT  MediciNova to Conduct Mouse Study under Partnership with BARDA to   GlobeNewswire Inc
Jun 27, 2021
06:31AM EDT  MNOV: Positive Results for MN-166 in Phase 2 AUD   Benzinga
Jun 22, 2021
02:43PM EDT  MediciNov Sees Volume After Zacks Research Raises Price Target To $28   Benzinga
Jun 21, 2021
10:56AM EDT  MediciNova, Inc. (MNOV) shares are trading above 17 percent on Monday morning after the company announced positive results from phase 2 trial of MN-166 or ibudilast in alcohol use disorder or AUD.   RTTNews
06:53AM EDT  Biopharmaceutical company MediciNova, Inc. (MNOV) announced Monday positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD).   RTTNews
06:36AM EDT  MediciNova Announces Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder   RTTNews
06:30AM EDT  MediciNova Announces Positive Results from Phase 2 Trial of MN-166 in Alcohol Use Disorder Published in Nature's Translational Psychiatry Journal   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Natures Translational Psychiatry.   GlobeNewswire Inc
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 14, 2021
06:30AM EDT  MediciNova to Participate in Maxim Group LLC Fireside Chat   GlobeNewswire Inc
Jun 7, 2021
06:31AM EDT  MediciNova Initiates Sheep Study Under Partnership With BARDA To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-Induced Lung Injury   Benzinga
06:30AM EDT  MediciNova Initiates Sheep Study under Partnership with BARDA to   GlobeNewswire Inc
Jun 2, 2021
06:41AM EDT  MNOV: Phase 3 ALS Trial Ongoing   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
05:41PM EDT  MediciNova Q2 EPS $0.00, Up From $(0.06) YoY   Benzinga
04:30PM EDT  - Completed $20M private placement financing with 3D Investment Partners -   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
Apr 22, 2021
06:30AM EDT  MediciNova Receives Gene Therapy Milestone Payments of $4M   Benzinga
06:30AM EDT  MediciNova Receives Gene Therapy Milestone Payments   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
06:30AM EDT  MediciNova to Participate in the B. Riley Neuroscience Conference   GlobeNewswire Inc
Apr 15, 2021
06:30AM EDT  MediciNova to Participate in the UBS Global Healthcare Virtual   GlobeNewswire Inc
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Mar 15, 2021
09:52AM EDT  MediciNova Shares Spiking Higher; Hearing Unknown Research Firm Sets $23 Price Target   Benzinga
Mar 10, 2021
02:37PM EST  Mid-Afternoon Market Update: Dow Surges 500 Points; US Budget Deficit Widens In February   Benzinga
12:53PM EST  Mid-Day Market Update: Dow Jumps Over 400 Points; Just Energy Shares Slide   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets Open Higher; Campbell Soup Reports In-Line Earnings   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2021   Benzinga
09:59AM EST  Shares of MediciNova Inc (MNOV) are surging over 67% Wednesday morning, following the biopharmaceutical company's announcement on a partnership with BARDA to develop chlorine gas-induced lung injury treatment.   RTTNews
09:32AM EST  Maxim Group Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $15   Benzinga
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
Mar 9, 2021
05:42PM EST  Shares of MediciNova Inc. (MNOV) surged over 100% in extended trading session on Tuesday after the biopharmaceutical company announced a partnership with BARDA to develop MN-166 as a medical countermeasure against chlorine gas-induced lung injury.   RTTNews
04:00PM EST  MediciNova Reports Partnership With Biomedical Advanced Research and Development Authority (BARDA) To Develop MN-166 As Medical Countermeasure Against Chlorine Gas-Induced Lung Injury   Benzinga
04:00PM EST  MediciNova Announces Partnership with BARDA to Develop MN-166   GlobeNewswire Inc
Mar 8, 2021
06:50AM EST  MediciNova to Participate in M Vest LLC and Maxim Group LLC   GlobeNewswire Inc
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
06:31AM EST  MediciNova To Discontinue Development Of A SARS-CoV-2 Vaccine   Benzinga
06:30AM EST  MediciNova Announces Update on   GlobeNewswire Inc
Jan 31, 2021
06:00PM EST  MediciNova Announces Closing of US$20 Million Private Placement   GlobeNewswire Inc
Jan 21, 2021
04:23PM EST  MediciNova 13D From 3D Investment Partners Shows 11.3% Stake In Co.   Benzinga
Jan 18, 2021
06:03PM EST  MediciNova Received Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of ALS in Japan   Benzinga
06:00PM EST  MediciNova Receives Notice of Allowance forNew Patent   GlobeNewswire Inc
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 11, 2021
09:30PM EST  MediciNova Enters into US$20 Million Securities Purchase Agreement   GlobeNewswire Inc
Dec 29, 2020
06:44AM EST  MediciNova Inc. (MNOV) said Tuesday that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis.   RTTNews
06:32AM EST  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166   RTTNews
06:31AM EST  MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For Treatment Of Progressive MS   Benzinga
06:30AM EST  MediciNova Receives Notice of Allowance forNew Patent   GlobeNewswire Inc
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
06:30AM EST  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 21, 2020.   GlobeNewswire Inc
Nov 25, 2020
06:33AM EST  MediciNova Announces Positive Optical Coherence Tomography Results From SPRINT-MS Phase 2b Trial Of MN-166   RTTNews
06:32AM EST  MediciNova Highlights Publication Of SPRINT-MS Phase 2b Trial Of MN-166 Trial In Multiple Sclerosis Journal   Benzinga
06:30AM EST  MediciNova Announces Positive Optical Coherence Tomography Results   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
06:33AM EST  MediciNova Announces Initiation Of Master Virus Seed Stock Production For Its Intranasal COVID-19 Vaccine Using BC-PIV Vector Technology   Benzinga
06:30AM EST  MediciNova Announces Initiation of Master Virus Seed Stock   GlobeNewswire Inc
Nov 13, 2020
05:35AM EST  MediciNova Announced Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience 2020   Benzinga
Oct 22, 2020
06:38AM EDT  MediciNova, In Collaboration With University Of Sydney And The Australasian Gastro-Intestinal Trials Group, Announces Plans For A Multi-center, Phase 2b Study To Evaluate MN-166 (ibudilast) In Chemotherapy-Induced Peripheral Neuropathy   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-controlled, randomized Phase 2b trial to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy (CIPN).   GlobeNewswire Inc
Oct 21, 2020
06:34AM EDT  MediciNova Appoints Carolyn Beaver To Its Board   RTTNews
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Ms. Carolyn Beaver to its Board of Directors and as Chair of its Audit Committee.   GlobeNewswire Inc
Oct 13, 2020
06:32AM EDT  MediciNova To Present Findings On MN-001 In Acute Liver Injury Model At The Liver Meeting Digital Experience 2020 Nov. 13-16   Benzinga
06:30AM EDT  MediciNova Announces Positive Findings on MN-001 (tipelukast) in   GlobeNewswire Inc
Sep 24, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Surges 250 Points; Owens & Minor Shares Spike Higher   Benzinga
02:05PM EDT  Mid-Day Market Update: US Stocks Turn Higher; Kubient Shares Plunge   Benzinga
06:34AM EDT  MediciNova: Positive Clinical Findings Published In Cancer Chemotherapy And Pharmacology On MN-166   RTTNews
06:32AM EDT  MediciNova Announces Positive Clinical Results Regarding MN-166 for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive clinical findings published in Cancer Chemotherapy and Pharmacology regarding MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy (CIPN).   GlobeNewswire Inc
Sep 23, 2020
11:29AM EDT  Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates   Benzinga
10:29AM EDT  MediciNova, Inc. (MNOV) shares are rising on Wednesday morning trade after the biopharma company announced the intranasal SARS CoV-2 vaccine prototype for COVID-19.   RTTNews
10:11AM EDT  Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates   Benzinga
09:27AM EDT  MediciNova Inc.'s (MNOV) intranasal BC-PIV SARS-CoV-2 vaccine has successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.   RTTNews
06:46AM EDT  MediciNova Says Intranasal BC-PIV SARS-CoV-2 Vaccine Induced Systemic IgG & Mucosal IgA Neutralizing Antibodies In Mice   RTTNews
06:45AM EDT  MediciNova: Intranasal BC-PIV SARS-CoV-2 Vaccine Induced Systemic IgG And Mucosal IgA Neutralizing Antibodies In Mice   RTTNews
06:32AM EDT  MediciNova Announces Its Intranasal COVID-19 Vaccine 'Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology'   Benzinga
06:30AM EDT  MediciNova Announces that its Intranasal COVID-19 Vaccine   GlobeNewswire Inc
Sep 11, 2020
06:39AM EDT  BioComo: Intranasal RS Virus Vaccine Induced Neutralizing Antibodies Against RS Virus In Mice Using BC-PIV Technology   RTTNews
06:32AM EDT  MediciNova Reports Co Developer Of Co.'s Coronavirus Vaccine, BioComo, Announced Its Respiratory Syncytial Virus Vaccine Using BC-PIV Technology Induced High Neutralizing Antibodies In Mice   Benzinga
06:30AM EDT  MediciNova Announces that BioComos Intranasal RS   GlobeNewswire Inc
Sep 1, 2020
06:32AM EDT  MediciNova Says 'we have confirmed that the SARS-CoV-2 specific protein antigen mounted on their membrane surfaces binds with ACE2, which is a known receptor of SARS-CoV-2.'   Benzinga
06:32AM EDT  MediciNova Announces 'Development Progress' On Intranasal Formulation Of SARS-CoV-2 Vaccine For COVID-19   Benzinga
06:30AM EDT  MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a viral vector platform technology developed by Mie University and BioComo.   GlobeNewswire Inc
Aug 6, 2020
01:24PM EDT  MediciNova shares are trading higher after the company announced the results from its phase 2 trial of MN-166 in alcohol disorder demonstrated that ibudilast significantly reduced basal, daily alcohol craving in AUD patients.   Benzinga
07:33AM EDT  MediciNova Announces Presentation Of Positive Results From Phase 2 Trial Of MN-166 In Alcohol Use Disorder At The American Psychological Association 2020 Annual Convention   Benzinga
06:30AM EDT  MediciNova Announces the Presentation of Positive Results from   GlobeNewswire Inc
Aug 4, 2020
06:30AM EDT  MediciNova to Participate in the Morgan Stanley Virtual 18th   GlobeNewswire Inc
Jul 28, 2020
12:05PM EDT  Mid-Day Market Update: Crude Oil Down Over 1%; Eastman Kodak Shares Jump   Benzinga
10:15AM EDT  Mid-Morning Market Update: Markets Open Lower; McDonald's Profit Misses Views   Benzinga
09:47AM EDT  Morning Market Stats in 5 Minutes   Benzinga
Jul 27, 2020
02:54PM EDT  Mid-Afternoon Market Update: Nasdaq Surges 140 Points; MediciNova Shares Spike Higher   Benzinga
12:07PM EDT  Mid-Day Market Update: Gold Jumps 2%; WiMi Hologram Cloud Shares Plummet   Benzinga
10:25AM EDT  Shares of MediciNova, Inc. (MNOV) are currently gaining nearly 25% after the company said it is developing vaccine for coronavirus in collaboration with BioComo and Mie University Japan.   RTTNews
07:35AM EDT  MediciNova, Inc. (MNOV) has reached a deal with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.   RTTNews
06:53AM EDT  MediciNova Enters Agreement With BioComo, Mie University For Joint Development Of SARS-CoV-2 Vaccine   RTTNews
06:34AM EDT  MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan   Benzinga
06:30AM EDT  MediciNova Announces SARS-CoV-2 Vaccine Joint Development with   GlobeNewswire Inc
Jul 20, 2020
06:30AM EDT  MediciNova to Participate in Panel Discussion at the B. Riley FBR   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC